Navigation Links
Ansun BioPharma Announces Potent in-vitro DAS181 Activity against Respiratory Syncytial Virus at 5th Congress of Virology
Date:12/8/2015

SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV. "This is very important data as RSV is a common respiratory pathogen and additional treatments are needed," noted Dr. Moss. "As DAS181 is currently in the clinic being studied for the treatment of other respiratory viruses, clinical trials are warranted to test the efficacy of this drug against RSV infection as well," commented Dr. Moss.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  DAS181 has two indications in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. Preclinical data suggests that DAS181 may have additional activity against other respiratory viruses. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

 


'/>"/>
SOURCE Ansun BioPharma
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
4. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
5. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
6. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
7. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
10. Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
11. PDL BioPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... (PRWEB) , ... December 12, 2018 , ... ... other life science software solutions, announces the Limfinity® ML (Machine Learning) addition for ... trained machine learning models within Limfinity® solutions. In the module, trained models make ...
(Date:12/10/2018)... China and SAN DIEGO (PRWEB) , ... ... ... MabPlex International, Ltd., a fully integrated Contract Development and Manufacturing Organization (CDMO) ... development, process characterization, conjugation optimization, cGMP manufacturing, and aseptic fill finish solutions ...
(Date:12/5/2018)... ... December 05, 2018 , ... STRmix™ – sophisticated forensic software ... – has been used to convict a Wyoming man of third-degree sexual assault, a ... used STRmix™ to test for DNA on the couch cushions on which the sexual ...
Breaking Biology Technology:
(Date:12/13/2018)... ROCHELLE, Va. (PRWEB) , ... December 12, 2018 ... ... today that Dr. Vinod Shah, one of the firm’s prominent Expert Consultants, was ... Leader Award. The award recognizes leaders who are working in pharmaceutical science, technology, ...
(Date:12/13/2018)... ... 12, 2018 , ... Illumina, Kaiser Permanente, ResMed and Aetna were just a ... team-building and cooking events company has hosted an impressive guest list of Fortune 500 ... , Each group who visits receives a completely customized experience, right down to the ...
(Date:12/13/2018)... ... December 13, 2018 , ... Biocompare, ... documentary entitled “What Researchers Need to Know about Antibody Manufacturing” . This ... Research series. The goal of this film is to educate scientists about antibody ...
Breaking Biology News(10 mins):